Logo of pnasPNASInfo for AuthorsSubscriptionsAboutThis Article
Proc Natl Acad Sci U S A. 1995 Sep 12; 92(19): 8955–8959.
PMCID: PMC41086

Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.

Abstract

Activated components of the complement system are potent mediators of inflammation that may play an important role in numerous disease states. For example, they have been implicated in the pathogenesis of inflammatory joint diseases including rheumatoid arthritis (RA). To target complement activation in immune-mediated joint inflammation, we have utilized monoclonal antibodies (mAbs) that inhibit the complement cascade at C5, blocking the generation of the major chemotactic and proinflammatory factors C5a and C5b-9. In this study, we demonstrate the efficacy of a mAb specific for murine C5 in the treatment of collagen-induced arthritis, an animal model for RA. We show that systemic administration of the anti-C5 mAb effectively inhibits terminal complement activation in vivo and prevents the onset of arthritis in immunized animals. Most important, anti-C5 mAb treatment is also highly effective in ameliorating established disease. These results demonstrate a critical role for activated terminal complement components not only in the induction but also in the progression of collagen-induced arthritis and suggest that C5 may be an attractive therapeutic target in RA.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.5M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ward PA, Zvaifler NJ. Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest. 1971 Mar;50(3):606–616. [PMC free article] [PubMed]
  • Morgan BP, Daniels RH, Williams BD. Measurement of terminal complement complexes in rheumatoid arthritis. Clin Exp Immunol. 1988 Sep;73(3):473–478. [PMC free article] [PubMed]
  • Makinde VA, Senaldi G, Jawad AS, Berry H, Vergani D. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway. Ann Rheum Dis. 1989 Apr;48(4):302–306. [PMC free article] [PubMed]
  • Daniels RH, Houston WA, Petersen MM, Williams JD, Williams BD, Morgan BP. Stimulation of human rheumatoid synovial cells by non-lethal complement membrane attack. Immunology. 1990 Feb;69(2):237–242. [PMC free article] [PubMed]
  • Brodeur JP, Ruddy S, Schwartz LB, Moxley G. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum. 1991 Dec;34(12):1531–1537. [PubMed]
  • Jose PJ, Moss IK, Maini RN, Williams TJ. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann Rheum Dis. 1990 Oct;49(10):747–752. [PMC free article] [PubMed]
  • Høgåsen K, Mollnes TE, Harboe M, Götze O, Hammer HB, Oppermann M. Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J Rheumatol. 1995 Jan;22(1):24–28. [PubMed]
  • Jasin HE. Immune mediated cartilage destruction. Scand J Rheumatol Suppl. 1988;76:111–116. [PubMed]
  • Gerard C, Gerard NP. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol. 1994;12:775–808. [PubMed]
  • Konteatis ZD, Siciliano SJ, Van Riper G, Molineaux CJ, Pandya S, Fischer P, Rosen H, Mumford RA, Springer MS. Development of C5a receptor antagonists. Differential loss of functional responses. J Immunol. 1994 Nov 1;153(9):4200–4205. [PubMed]
  • Nicholson-Weller A, Halperin JA. Membrane signaling by complement C5b-9, the membrane attack complex. Immunol Res. 1993;12(3):244–257. [PubMed]
  • Stuart JM, Townes AS, Kang AH. Collagen autoimmune arthritis. Annu Rev Immunol. 1984;2:199–218. [PubMed]
  • Frei Y, Lambris JD, Stockinger B. Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies. Mol Cell Probes. 1987 Jun;1(2):141–149. [PubMed]
  • Wooley PH, Luthra HS, Stuart JM, David CS. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med. 1981 Sep 1;154(3):688–700. [PMC free article] [PubMed]
  • Spinella DG, Jeffers JR, Reife RA, Stuart JM. The role of C5 and T-cell receptor Vb genes in susceptibility to collagen-induced arthritis. Immunogenetics. 1991;34(1):23–27. [PubMed]
  • Andersson M, Goldschmidt TJ, Michaelsson E, Larsson A, Holmdahl R. T-cell receptor V beta haplotype and complement component C5 play no significant role for the resistance to collagen-induced arthritis in the SWR mouse. Immunology. 1991 Jun;73(2):191–196. [PMC free article] [PubMed]
  • Banerjee S, Anderson GD, Luthra HS, David CS. Influence of complement C5 and V beta T cell receptor mutations on susceptibility to collagen-induced arthritis in mice. J Immunol. 1989 Apr 1;142(7):2237–2243. [PubMed]
  • Ranges GE, Sriram S, Cooper SM. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med. 1985 Sep 1;162(3):1105–1110. [PMC free article] [PubMed]
  • Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2762–2766. [PMC free article] [PubMed]
  • Barton PA, Warren JS. Complement component C5 modulates the systemic tumor necrosis factor response in murine endotoxic shock. Infect Immun. 1993 Apr;61(4):1474–1481. [PMC free article] [PubMed]
  • Mattsson E, Rollof J, Verhoef J, Van Dijk H, Fleer A. Serum-induced potentiation of tumor necrosis factor alpha production by human monocytes in response to staphylococcal peptidoglycan: involvement of different serum factors. Infect Immun. 1994 Sep;62(9):3837–3843. [PMC free article] [PubMed]
  • Rothstein JL, Lint TF, Schreiber H. Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5). J Exp Med. 1988 Dec 1;168(6):2007–2021. [PMC free article] [PubMed]
  • Fava RA, Gates C, Townes AS. Critical role of peripheral blood phagocytes and the involvement of complement in tumour necrosis factor enhancement of passive collagen-arthritis. Clin Exp Immunol. 1993 Nov;94(2):261–266. [PMC free article] [PubMed]
  • Wetsel RA, Kolb WP. Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with noncomplement enzymes without release of polypeptide fragments. J Exp Med. 1983 Jun 1;157(6):2029–2048. [PMC free article] [PubMed]
  • Würzner R, Schulze M, Happe L, Franzke A, Bieber FA, Oppermann M, Götze O. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm. 1991;8(5-6):328–340. [PubMed]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

Formats:

Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...